An attempt has been made to delineate the role of natural and synthetic retinoid receptor ligands on vimentin expression in the human triple-negative breast cancer cells. The effects of currently synthesized triorganotin derivatives of the general formula R3SnX (R is butyl or phenyl, X is isothiocyanate), which are considered RXR ligands, were investigated in the human MDA-MB-231 breast cancer cell line. Studies were evaluated in the presence and absence of all-trans retinoic acid (ATRA), a natural RAR ligand. Vimentin represents the major protein associated with epithelial-mesenchymal transition (EMT), an essential process when the primary tumour transforms into a malignant one. mRNA and proteomic data obtained in this study, based on the PDQuest software protein evaluation and further quantification of proteins by iTRAQ analysis, suggest that vimentin was significantly reduced in the combination of RAR ligand and RXR ligand treatment. Both tested triorganotin compounds showed similarly reduced expression of vimentin, but tributyltin isothiocyanate (TBT-ITC) proved to be more effective than triphenyltin isothiocyanate (TPT-ITC). Furthermore, the effect of natural (9cRA) and synthetic RXR ligands, both chloride and isothiocyanate derivatives, on vimentin expression was compared.

Department of Chemical Drugs Faculty of Pharmacy University of Veterinary and Pharmaceutical Sciences Brno Palackeho 1946 1 612 42 Brno Czech Republic

Institute of Analytical Chemistry of the CAS Veveri 97 602 00 Brno Czech Republic

Institute of Experimental Endocrinology Biomedical Research Centre Slovak Academy of Sciences Dubravska cesta 9 845 05 Bratislava Slovak Republic

000      

00000naa a2200000 a 4500

001      

bmc19044502

003      

CZ-PrNML

005      

20200120102908.0

007      

ta

008      

200109s2020 ne f 000 0|eng||

009      

AR

024    7_

$a 10.1016/j.toxlet.2019.10.004 $2 doi

035    __

$a (PubMed)31634547

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a ne

100    1_

$a Strouhalova, Dana $u Institute of Analytical Chemistry of the CAS, Veveri 97, 602 00 Brno, Czech Republic.

245    10

$a Down-regulation of vimentin by triorganotin isothiocyanates-nuclear retinoid X receptor agonists: A proteomic approach / $c D. Strouhalova, D. Macejova, B. Mosna, P. Bobal, J. Otevrel, M. Lastovickova, J. Brtko, J. Bobalova,

520    9_

$a An attempt has been made to delineate the role of natural and synthetic retinoid receptor ligands on vimentin expression in the human triple-negative breast cancer cells. The effects of currently synthesized triorganotin derivatives of the general formula R3SnX (R is butyl or phenyl, X is isothiocyanate), which are considered RXR ligands, were investigated in the human MDA-MB-231 breast cancer cell line. Studies were evaluated in the presence and absence of all-trans retinoic acid (ATRA), a natural RAR ligand. Vimentin represents the major protein associated with epithelial-mesenchymal transition (EMT), an essential process when the primary tumour transforms into a malignant one. mRNA and proteomic data obtained in this study, based on the PDQuest software protein evaluation and further quantification of proteins by iTRAQ analysis, suggest that vimentin was significantly reduced in the combination of RAR ligand and RXR ligand treatment. Both tested triorganotin compounds showed similarly reduced expression of vimentin, but tributyltin isothiocyanate (TBT-ITC) proved to be more effective than triphenyltin isothiocyanate (TPT-ITC). Furthermore, the effect of natural (9cRA) and synthetic RXR ligands, both chloride and isothiocyanate derivatives, on vimentin expression was compared.

650    _2

$a antitumorózní látky $x farmakologie $7 D000970

650    _2

$a nádory prsu $x farmakoterapie $x metabolismus $x patologie $7 D001943

650    _2

$a nádorové buněčné linie $7 D045744

650    _2

$a down regulace $7 D015536

650    _2

$a 2D gelová elektroforéza $7 D015180

650    _2

$a epitelo-mezenchymální tranzice $x účinky léků $7 D058750

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a organocínové sloučeniny $x farmakologie $7 D009947

650    _2

$a proteomika $x metody $7 D040901

650    _2

$a retinoidní X receptory $x agonisté $x metabolismus $7 D047488

650    _2

$a signální transdukce $x účinky léků $7 D015398

650    _2

$a spektrometrie hmotnostní - ionizace laserem za účasti matrice $7 D019032

650    _2

$a tandemová hmotnostní spektrometrie $7 D053719

650    _2

$a tretinoin $x farmakologie $7 D014212

650    _2

$a trialkylcínové sloučeniny $x farmakologie $7 D014220

650    _2

$a vimentin $x metabolismus $7 D014746

655    _2

$a srovnávací studie $7 D003160

655    _2

$a časopisecké články $7 D016428

700    1_

$a Macejova, Dana $u Institute of Experimental Endocrinology, Biomedical Research Centre, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic.

700    1_

$a Mosna, Barbora $u Institute of Experimental Endocrinology, Biomedical Research Centre, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic.

700    1_

$a Bobal, Pavel $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackeho 1946/1, 612 42 Brno, Czech Republic.

700    1_

$a Otevrel, Jan $u Department of Chemical Drugs, Faculty of Pharmacy, University of Veterinary and Pharmaceutical Sciences Brno, Palackeho 1946/1, 612 42 Brno, Czech Republic.

700    1_

$a Lastovickova, Marketa $u Institute of Analytical Chemistry of the CAS, Veveri 97, 602 00 Brno, Czech Republic.

700    1_

$a Brtko, Julius $u Institute of Experimental Endocrinology, Biomedical Research Centre, Slovak Academy of Sciences, Dubravska cesta 9, 845 05 Bratislava, Slovak Republic.

700    1_

$a Bobalova, Janette $u Institute of Analytical Chemistry of the CAS, Veveri 97, 602 00 Brno, Czech Republic. Electronic address: bobalova@iach.cz.

773    0_

$w MED00004537 $t Toxicology letters $x 1879-3169 $g Roč. 318, č. - (2020), s. 22-29

856    41

$u https://pubmed.ncbi.nlm.nih.gov/31634547 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20200109 $b ABA008

991    __

$a 20200120103244 $b ABA008

999    __

$a ok $b bmc $g 1482771 $s 1083175

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2020 $b 318 $c - $d 22-29 $e 20191018 $i 1879-3169 $m Toxicology letters $n Toxicol Lett $x MED00004537

LZP    __

$a Pubmed-20200109